To read the full story
Related Article
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Takeda’s Hyqvia Nabs European Approval for CIDP Maintenance Therapy
January 31, 2024
- Takeda’s Hyqvia Earns US Nod for CIDP Maintenance Therapy
January 18, 2024
- Takeda’s Hyqvia Gets EU Panel Backing for CIDP Maintenance Therapy
December 19, 2023
- Takeda’s Hyqvia Smashes Primary Goal in Global PIII for CIDP
July 25, 2022
BUSINESS
- Japan’s 1st Tick-Borne Encephalitis Vaccine Now Available: Pfizer
September 17, 2024
- Taisho Seeks Japan Nod for Insomnia Med Vornorexant
September 13, 2024
- Opdivo-Yervoy Filed for 1st Line Use in MSI-H Colorectal Cancer in Japan
September 13, 2024
- Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
- IBM, Kobe Biomedical Cluster Join Hands to Expedite Clinical Trials with AI
September 12, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…